title: [Efficacy of FAEV regimen in treatment of high-risk drug-resistant gestational trophoblastic tumor].
abstract: OBJECTIVE
  To evaluate the efficacy of floxuridine, actinomycin D, etoposide, vincristine (FAEV) regimen in treatment of high-risk drug-resistant gestational trophoblastic tumor (GTT).
  
  
  METHODS
  From October 2001 to May 2004, 11 cases of high-risk drug-resistant GTT were treated with FAEV regimen. The International Federation of Gynecology and Obstetrics (FIGO) prognosis score (2000) was 7 to 13 (median 9). All patients were referred to Peking Union Medical College Hospital because of failure of chemotherapy previously. After the FAEV treatment, they were followed up for 15 to 42 months.
  
  
  RESULTS
  Seven cases (64%, 7/11) were cured by FAEV regimen. The median treatment course for serum human chorionic gonadotropin reaching normal level was 3. Four cases (36%, 4/11) showed drug-resistant to FAEV regimen. The major side effect of FAEV regimen was myelosuppression. Granulocyte colony stimulating factor support was needed after 98% (63/64) of the courses.
  
  
  CONCLUSIONS
  For those high-risk drug-resistant GTT cases, FAEV regimen could be considered as an effective choice of treatment.
authors.affiliation: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing 100730, China.
authors.forename: Xi-run
authors.initials: XR
authors.lastname: Wan
authors.forename: Yang
authors.initials: Y
authors.lastname: Xiang
authors.forename: Xiu-yu
authors.initials: XY
authors.lastname: Yang
authors.forename: Yu
authors.initials: Y
authors.lastname: Wu
authors.forename: Ning
authors.initials: N
authors.lastname: Liu
authors.forename: Ling
authors.initials: L
authors.lastname: Chen
authors.forename: Ruo-fan
authors.initials: RF
authors.lastname: Dong
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood; D003609:Dactinomycin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D005500:Follow-Up Studies; D031901:Gestational Trophoblastic Disease / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011247:Pregnancy; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D018997:Chorionic Gonadotropin, beta Subunit, Human; D005467:Floxuridine; D003609:Dactinomycin; D014750:Vincristine; D005047:Etoposide